Loading…
Prognostic significance of pronormoblasts in erythrocyte predominant myelodysplastic patients
Recent studies of acute erythroleukemias have reaffirmed DiGuglielmo's syndrome (M6a, myeloblast‐predominant) and disease (M6b, pronormoblast‐predominant). M6c (mixed myeloblast/pronormoblast) has also been described. However, MDS is still defined according to the percentage of myeloblasts (% m...
Saved in:
| Published in: | American journal of hematology 2006-07, Vol.81 (7), p.484-491 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4193-20ad693df0bf3e51ff726b23e2e24494627b539c8a4710d0747a1f76fa327b123 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4193-20ad693df0bf3e51ff726b23e2e24494627b539c8a4710d0747a1f76fa327b123 |
| container_end_page | 491 |
| container_issue | 7 |
| container_start_page | 484 |
| container_title | American journal of hematology |
| container_volume | 81 |
| creator | Mazzella, Fermina M. Smith, David Horn, Paul Cotelingam, James D. Rector, James T. Shrit, M. Atef Pesce, Amadeo Schumacher, Harold R. |
| description | Recent studies of acute erythroleukemias have reaffirmed DiGuglielmo's syndrome (M6a, myeloblast‐predominant) and disease (M6b, pronormoblast‐predominant). M6c (mixed myeloblast/pronormoblast) has also been described. However, MDS is still defined according to the percentage of myeloblasts (% myeloblasts) without including the pronormoblast count.
A 20‐year retrospective study was performed to identify cases demonstrating ≥50% erythrocytic component and |
| doi_str_mv | 10.1002/ajh.20563 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68061119</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68061119</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4193-20ad693df0bf3e51ff726b23e2e24494627b539c8a4710d0747a1f76fa327b123</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhoMouq4e_APSi4KHXWeSNmmPIn6yoAc9SknTRCNtsiZdpP_e6C54Ek8zMA_vOzyEHCHMEYCey_e3OYWCsy0yQaj4rOQF3SYTYBzTDtUe2Y_xHQAxL2GX7CEXRVHwckJeHoN_dT4OVmXRvjprrJJO6cybbBm886H3TSfjEDPrMh3G4S14NQ46XXXre-ukG7J-1J1vx7j8JlPSUg5WuyEekB0ju6gPN3NKnq-vni5vZ4uHm7vLi8VM5VixGQXZ8oq1BhrDdIHGCMobyjTVNM-rnFPRFKxSpcwFQgsiFxKN4EaydEHKpuR0nZte_ljpONS9jUp3nXTar2LNS-CIqeo_ECvBcuAsgWdrUAUfY9CmXgbbyzDWCPW39DpJr3-kJ_Z4E7pqet3-khvLCTjZADIq2ZmQDNv4y4mKAqbWKTlfc5-20-PfjfXF_e26-gtkD5mv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19734063</pqid></control><display><type>article</type><title>Prognostic significance of pronormoblasts in erythrocyte predominant myelodysplastic patients</title><source>Wiley</source><creator>Mazzella, Fermina M. ; Smith, David ; Horn, Paul ; Cotelingam, James D. ; Rector, James T. ; Shrit, M. Atef ; Pesce, Amadeo ; Schumacher, Harold R.</creator><creatorcontrib>Mazzella, Fermina M. ; Smith, David ; Horn, Paul ; Cotelingam, James D. ; Rector, James T. ; Shrit, M. Atef ; Pesce, Amadeo ; Schumacher, Harold R.</creatorcontrib><description>Recent studies of acute erythroleukemias have reaffirmed DiGuglielmo's syndrome (M6a, myeloblast‐predominant) and disease (M6b, pronormoblast‐predominant). M6c (mixed myeloblast/pronormoblast) has also been described. However, MDS is still defined according to the percentage of myeloblasts (% myeloblasts) without including the pronormoblast count.
A 20‐year retrospective study was performed to identify cases demonstrating ≥50% erythrocytic component and <30% calculated blasts (FAB exclusion criteria) without underlying cause (96 cases). Pronormoblast and myeloblast counts and other variables were analyzed as possible explanatory variables of the variations in survival.
Considered alone, increasing % myeloblasts and/or percentage of pronormoblasts (% pronormoblasts) were significant predictors of decreasing survival. When all variables were considered as a multivariate group, the best fitting statistical model for predicting survival was a function of age, % pronormoblasts, IPSS cytopenias, platelet count, and percentage erythrocytic component. Of these, % pronormoblasts was by far the most significant. Nonappearance of % myeloblasts in this model is indicative of high correlations of this count with other variables. Am. J. Hematol. 81:484–491, 2006. © 2006 Wiley‐Liss, Inc.</description><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.20563</identifier><identifier>PMID: 16755568</identifier><identifier>CODEN: AJHEDD</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Age Factors ; Biological and medical sciences ; blast ; Disease-Free Survival ; Erythroblasts - pathology ; Erythrocyte Count ; Erythrocytes - pathology ; erythroid hyperplasia ; erythroleukemia ; Granulocyte Precursor Cells - pathology ; Hematologic and hematopoietic diseases ; Humans ; Leukemia, Erythroblastic, Acute - mortality ; Leukemia, Erythroblastic, Acute - pathology ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Middle Aged ; Models, Statistical ; Multivariate Analysis ; myelodysplastic syndrome ; Myelodysplastic Syndromes - mortality ; Myelodysplastic Syndromes - pathology ; Platelet Count ; Predictive Value of Tests ; Prognosis ; pronormoblast ; Retrospective Studies</subject><ispartof>American journal of hematology, 2006-07, Vol.81 (7), p.484-491</ispartof><rights>Copyright © 2006 Wiley‐Liss, Inc.</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4193-20ad693df0bf3e51ff726b23e2e24494627b539c8a4710d0747a1f76fa327b123</citedby><cites>FETCH-LOGICAL-c4193-20ad693df0bf3e51ff726b23e2e24494627b539c8a4710d0747a1f76fa327b123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17920106$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16755568$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mazzella, Fermina M.</creatorcontrib><creatorcontrib>Smith, David</creatorcontrib><creatorcontrib>Horn, Paul</creatorcontrib><creatorcontrib>Cotelingam, James D.</creatorcontrib><creatorcontrib>Rector, James T.</creatorcontrib><creatorcontrib>Shrit, M. Atef</creatorcontrib><creatorcontrib>Pesce, Amadeo</creatorcontrib><creatorcontrib>Schumacher, Harold R.</creatorcontrib><title>Prognostic significance of pronormoblasts in erythrocyte predominant myelodysplastic patients</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><description>Recent studies of acute erythroleukemias have reaffirmed DiGuglielmo's syndrome (M6a, myeloblast‐predominant) and disease (M6b, pronormoblast‐predominant). M6c (mixed myeloblast/pronormoblast) has also been described. However, MDS is still defined according to the percentage of myeloblasts (% myeloblasts) without including the pronormoblast count.
A 20‐year retrospective study was performed to identify cases demonstrating ≥50% erythrocytic component and <30% calculated blasts (FAB exclusion criteria) without underlying cause (96 cases). Pronormoblast and myeloblast counts and other variables were analyzed as possible explanatory variables of the variations in survival.
Considered alone, increasing % myeloblasts and/or percentage of pronormoblasts (% pronormoblasts) were significant predictors of decreasing survival. When all variables were considered as a multivariate group, the best fitting statistical model for predicting survival was a function of age, % pronormoblasts, IPSS cytopenias, platelet count, and percentage erythrocytic component. Of these, % pronormoblasts was by far the most significant. Nonappearance of % myeloblasts in this model is indicative of high correlations of this count with other variables. Am. J. Hematol. 81:484–491, 2006. © 2006 Wiley‐Liss, Inc.</description><subject>Age Factors</subject><subject>Biological and medical sciences</subject><subject>blast</subject><subject>Disease-Free Survival</subject><subject>Erythroblasts - pathology</subject><subject>Erythrocyte Count</subject><subject>Erythrocytes - pathology</subject><subject>erythroid hyperplasia</subject><subject>erythroleukemia</subject><subject>Granulocyte Precursor Cells - pathology</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Leukemia, Erythroblastic, Acute - mortality</subject><subject>Leukemia, Erythroblastic, Acute - pathology</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Models, Statistical</subject><subject>Multivariate Analysis</subject><subject>myelodysplastic syndrome</subject><subject>Myelodysplastic Syndromes - mortality</subject><subject>Myelodysplastic Syndromes - pathology</subject><subject>Platelet Count</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>pronormoblast</subject><subject>Retrospective Studies</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqFkE1LxDAQhoMouq4e_APSi4KHXWeSNmmPIn6yoAc9SknTRCNtsiZdpP_e6C54Ek8zMA_vOzyEHCHMEYCey_e3OYWCsy0yQaj4rOQF3SYTYBzTDtUe2Y_xHQAxL2GX7CEXRVHwckJeHoN_dT4OVmXRvjprrJJO6cybbBm886H3TSfjEDPrMh3G4S14NQ46XXXre-ukG7J-1J1vx7j8JlPSUg5WuyEekB0ju6gPN3NKnq-vni5vZ4uHm7vLi8VM5VixGQXZ8oq1BhrDdIHGCMobyjTVNM-rnFPRFKxSpcwFQgsiFxKN4EaydEHKpuR0nZte_ljpONS9jUp3nXTar2LNS-CIqeo_ECvBcuAsgWdrUAUfY9CmXgbbyzDWCPW39DpJr3-kJ_Z4E7pqet3-khvLCTjZADIq2ZmQDNv4y4mKAqbWKTlfc5-20-PfjfXF_e26-gtkD5mv</recordid><startdate>200607</startdate><enddate>200607</enddate><creator>Mazzella, Fermina M.</creator><creator>Smith, David</creator><creator>Horn, Paul</creator><creator>Cotelingam, James D.</creator><creator>Rector, James T.</creator><creator>Shrit, M. Atef</creator><creator>Pesce, Amadeo</creator><creator>Schumacher, Harold R.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200607</creationdate><title>Prognostic significance of pronormoblasts in erythrocyte predominant myelodysplastic patients</title><author>Mazzella, Fermina M. ; Smith, David ; Horn, Paul ; Cotelingam, James D. ; Rector, James T. ; Shrit, M. Atef ; Pesce, Amadeo ; Schumacher, Harold R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4193-20ad693df0bf3e51ff726b23e2e24494627b539c8a4710d0747a1f76fa327b123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Age Factors</topic><topic>Biological and medical sciences</topic><topic>blast</topic><topic>Disease-Free Survival</topic><topic>Erythroblasts - pathology</topic><topic>Erythrocyte Count</topic><topic>Erythrocytes - pathology</topic><topic>erythroid hyperplasia</topic><topic>erythroleukemia</topic><topic>Granulocyte Precursor Cells - pathology</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Leukemia, Erythroblastic, Acute - mortality</topic><topic>Leukemia, Erythroblastic, Acute - pathology</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Models, Statistical</topic><topic>Multivariate Analysis</topic><topic>myelodysplastic syndrome</topic><topic>Myelodysplastic Syndromes - mortality</topic><topic>Myelodysplastic Syndromes - pathology</topic><topic>Platelet Count</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>pronormoblast</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mazzella, Fermina M.</creatorcontrib><creatorcontrib>Smith, David</creatorcontrib><creatorcontrib>Horn, Paul</creatorcontrib><creatorcontrib>Cotelingam, James D.</creatorcontrib><creatorcontrib>Rector, James T.</creatorcontrib><creatorcontrib>Shrit, M. Atef</creatorcontrib><creatorcontrib>Pesce, Amadeo</creatorcontrib><creatorcontrib>Schumacher, Harold R.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mazzella, Fermina M.</au><au>Smith, David</au><au>Horn, Paul</au><au>Cotelingam, James D.</au><au>Rector, James T.</au><au>Shrit, M. Atef</au><au>Pesce, Amadeo</au><au>Schumacher, Harold R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic significance of pronormoblasts in erythrocyte predominant myelodysplastic patients</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>2006-07</date><risdate>2006</risdate><volume>81</volume><issue>7</issue><spage>484</spage><epage>491</epage><pages>484-491</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><coden>AJHEDD</coden><abstract>Recent studies of acute erythroleukemias have reaffirmed DiGuglielmo's syndrome (M6a, myeloblast‐predominant) and disease (M6b, pronormoblast‐predominant). M6c (mixed myeloblast/pronormoblast) has also been described. However, MDS is still defined according to the percentage of myeloblasts (% myeloblasts) without including the pronormoblast count.
A 20‐year retrospective study was performed to identify cases demonstrating ≥50% erythrocytic component and <30% calculated blasts (FAB exclusion criteria) without underlying cause (96 cases). Pronormoblast and myeloblast counts and other variables were analyzed as possible explanatory variables of the variations in survival.
Considered alone, increasing % myeloblasts and/or percentage of pronormoblasts (% pronormoblasts) were significant predictors of decreasing survival. When all variables were considered as a multivariate group, the best fitting statistical model for predicting survival was a function of age, % pronormoblasts, IPSS cytopenias, platelet count, and percentage erythrocytic component. Of these, % pronormoblasts was by far the most significant. Nonappearance of % myeloblasts in this model is indicative of high correlations of this count with other variables. Am. J. Hematol. 81:484–491, 2006. © 2006 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>16755568</pmid><doi>10.1002/ajh.20563</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 2006-07, Vol.81 (7), p.484-491 |
| issn | 0361-8609 1096-8652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68061119 |
| source | Wiley |
| subjects | Age Factors Biological and medical sciences blast Disease-Free Survival Erythroblasts - pathology Erythrocyte Count Erythrocytes - pathology erythroid hyperplasia erythroleukemia Granulocyte Precursor Cells - pathology Hematologic and hematopoietic diseases Humans Leukemia, Erythroblastic, Acute - mortality Leukemia, Erythroblastic, Acute - pathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Models, Statistical Multivariate Analysis myelodysplastic syndrome Myelodysplastic Syndromes - mortality Myelodysplastic Syndromes - pathology Platelet Count Predictive Value of Tests Prognosis pronormoblast Retrospective Studies |
| title | Prognostic significance of pronormoblasts in erythrocyte predominant myelodysplastic patients |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A26%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20significance%20of%20pronormoblasts%20in%20erythrocyte%20predominant%20myelodysplastic%20patients&rft.jtitle=American%20journal%20of%20hematology&rft.au=Mazzella,%20Fermina%20M.&rft.date=2006-07&rft.volume=81&rft.issue=7&rft.spage=484&rft.epage=491&rft.pages=484-491&rft.issn=0361-8609&rft.eissn=1096-8652&rft.coden=AJHEDD&rft_id=info:doi/10.1002/ajh.20563&rft_dat=%3Cproquest_cross%3E68061119%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4193-20ad693df0bf3e51ff726b23e2e24494627b539c8a4710d0747a1f76fa327b123%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=19734063&rft_id=info:pmid/16755568&rfr_iscdi=true |